Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of $1.70, $0.12 better than the analyst estimate of $1.58. Revenue for the quarter came in at $107.1 million versus the consensus estimate of $106.16 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.